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Abstract
Regenerative medicine is a promising approach to treat neurodegenerative diseases by
replacing degenerating cells like neurons or oligodendrocytes. Targeting human neural stem
cells directly in the brain is a big challenge in such a strategy. The neurofilament derived
NFL-TBS.40-63 peptide has recently been introduced as a novel tool to target neural stem
cells. Previous studies showed that this peptide can be internalized by rat neural stem cells in
vitro and in vivo, which coincided with lower proliferation and self-renewal capacity and
increase of differentiation. In this study, we analyzed the uptake and potential effects of the
NFL-TBS.40-63 peptide on human neural stem cells isolated from human fetuses. We
showed that the peptide inhibits proliferation and the ability to produce neurospheres in vitro,
which is consistent with an increase in cell adhesion and differentiation. These results confirm
that the peptide could be a promising molecule to target and manipulate human neural stem
cells and thus could serve as a strategic tool for regenerative medicine.
Introduction
Although there has been a steady increase in incidence rates for neurodegenerative diseases,
effective treatments are still lacking. Regenerative therapy could help to reduce symptoms and
reverse disease progression by replacing degenerative cells. Neural stem cells (NSCs) have the
capacity to self-renew, proliferate, migrate and differentiate into neurons, astrocytes or oligo-
dendrocytes in the central nervous system, and have become key targets for regenerative ther-
apy of neurodegenerative diseases [1]. Moreover, some studies showed that endogenous or
exogenous NSCs are able to migrate to brain tumors to protect the microenvironment from
the tumor [2]. Currently, preclinical studies investigate the therapeutic effect of fetal NSCs in
neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS). Indeed, fetal NSCs have
been transplanted into the lumbar or cervical segments of the spinal cord of ALS patients dur-
ing phase 1 clinical trials [3]. An increasing number of clinical studies use NSCs to treat neu-
rology diseases like neurodegenerative diseases, spinal cord injury or brain tumors [4–7].
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The potential source for cell therapy clinical studies in the central nervous system includes
human NSCs from fetuses, adults or pluripotent stem cells [1, 4]. The main source of endoge-
nous NSCs in the human adult brain is the subventricular and subgranular zones. These cells
thus need to be isolated from fetal tissue or adults after biopsy, grown in vitro and then trans-
planted into patients [8]. This procedure is difficult due to the low availability of tissues from
the brain and ethical challenges. Therefore, regenerative medicine could be improved by target-
ing NSCs directly in the brain (that will then migrate and differentiate into neurons or oligoden-
drocytes at the site of injury) without removing them from their endogenous environment.
A potential candidate for such an objective is the NFL-TBS.40-63 peptide, which corre-
sponds to the sequence of the tubulin-binding site (TBS) located on the neurofilament light
subunit (NFL) between amino acids 40 and 63 [9]. Previous works showed that this peptide
targets glioblastoma cells specifically (when compared to healthy cells like neurons or astro-
cytes), leading to a reduction in their viability, proliferation, and migration. When injected in
the intracerebral tumor, its volume is reduced by 70% after 24 days of treatment [10]. This pep-
tide not only increases oligodendrocyte differentiation and maturation, but also protects oligo-
dendrocytes in a demyelination model [11]. Recently, we showed that the peptide can target
newborn and adult rat NSCs (rNSCs), and modify rNSCs properties in vitro, in particular dif-
ferentiation [12].
To determine the feasibility of using this approach as a therapeutic strategy, it is crucial to
obtain the proof of concept that the NFL-TBS.40-63 peptide can also be internalized by human
NSCs (hNSCs), and evaluate possible effects in hNSCs after uptake. Here, we investigated the
in vitro internalization of the NFL-TBS.40-63 peptide in hNSCs isolated from human fetuses
and potential effects on their properties. We showed that the NFL-TBS.40-63 peptide enters
massively by direct translocation in these cells, without major effect on their viability at low
concentration (less than 40 µm). At higher concentrations, the peptide inhibits proliferation
and the ability to form neurospheres. These results are consistent with an increase in cell adhe-
sion and their more advanced differentiation state (in the neuronal and astrocytic pathways).
To our knowledge, this is the first report to show that a peptide can enter into hNSCs, leading
to modified stem cell properties including differentiation. This provides a promising tool to
target such cells during regenerative therapy.
Materials & Methods
Ethics statement
Human fetuses were obtained after legal abortion with written informed consent from the
patient. The procedure for the procurement and use of human fetal central nervous system tis-
sue was approved and monitored by the “Comite´ Consultatif de Protection des Personnes dans
la Recherche Biome´dicale” of Henri Mondor Hospital, France. The cells are declared at the
“Centre des Ressources Biologiques”of the University Hospital in Angers with reference num-
bers at the Research Ministry: declaration N˚ DC-2011-1467; authorization N˚ AC-2012-1507.
Cell culture and materials
The hNSCs used in this study were prepared from the central nervous system of first trimester
human fetuses, as previously described [13]. Briefly, the cortex was dissected and cut into
1-mm3 tissue pieces. After mechanical dissociation, single-cell suspensions were cultured in
DMEM/Ham’s F12 culture medium in a 3:1 mixture (Dulbecco’s modified Eagle medium with
L-glutamine (DMEM; Lonza, Levallois-Perret, France) and Ham’s F12 (Lonza) supplemented
with 1X B27 (Invitrogen Life Technologies, Saint Aubin, France), Epidermal Growth Factor
(EGF) (20 ng/ml; R&D systems), basic Fibroblast Growth Factor (bFGF) at 20 ng/ml (R&D
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systems, Minneapolis, MN 55413, USA), Heparin (5 µg/ml, Merck Millipore, ıˆle-de-France,
France), 100 U Penicillin, and 1,000 U Streptomycin (Sigma, Saint-Quentin Fallavier, France)).
This cell suspension generated proliferating clones containing hNSCs in floating spheres
(termed neurospheres). Cells were further expanded and maintained in suspension as neuro-
spheres in uncoated tissue culture dishes and the medium was changed twice a week. Cells
were maintained at 37˚C in a humidified atmosphere containing 5% CO2. The conditioned
medium was composed by DMEM/F12 (1:1) (Lonza) added by 1X B27 and 1X 100 U Penicil-
lin, and 1,000 U Streptomycin. This medium induced cell adhesion and differentiation of
hNSCs after 10 days in culture as described elsewhere [14, 15].
Peptides were synthetized by Genecust (Dudelange, Luxembourg), Genosphere (Paris,
France) or Polypeptide (Strasbourg, France). The NFL-TBS.40-63 peptide (YSSYSAPVSSSLS
VRRSYSSSSGS) was coupled to 6-carboxy-fluorescein (FAM) or biotin, and dissolved in ster-
ile water at 0.5 mmol/L.
Chlorpromazine hydrochloride (50 µmol/L), Nystatine (25 µg/ml), 5(N,N-dimethyl)
amiloride hydrochloride (DMA, 1 mmol/L), Sodium azide (10 mmol/L) and D-glucose (6
mmol/L) were obtained from Sigma. Paclitaxel (Life Technologies, Illkirch, France) or colchi-
cine (Sigma) was used as positive control in some techniques.
Internalization of the peptide in hNSCs
The uptake of the peptide by hNSCs was measured using the flow cytometer technique. Briefly,
hNSCs were seeded in 6-well plates and treated with increasing concentrations of FAM- cou-
pled NFL-TBS.40-63 peptide for an hour at 37˚C. To analyze the internalization mechanism,
cells were pre-incubated at 4˚C, with an ATP-depleted buffer (sodium azide at 10 mmol/L and
D-glucose at 6 mmol/L) or with a panel of endocytosis inhibitors for 30 minutes before the
addition of the peptide at 20 µmol/L. Incubation with the peptide was performed in the same
conditions. Cells were recovered, washed once with PBS (Phosphate Buffered Saline), and pel-
leted (1200 rpm– 5 minutes). Cell dissociation was performed with a 26 gauge needle and
incubated with 150 nmol/L calcein violet (Invitrogen) for 20 minutes before analysis with
Fluorescence-Activated Cell Sorting or flow cytometry (FACS) using BD FACSCanto II (BD
Biosciences, Le pont de Claix, France). A minimum of 10,000 events per sample were analyzed,
followed by data analysis with the Flowing Software (version 2.5.1).
To visualize the FAM-labeled peptide in hNSCs, cells were dissociated and seeded for 1
hour on coverslips coated with BD Cell-Tak (3.5 µg/cm) (Corning, Bedford, United Kingdom).
Then, they were incubated for 1 hour at 37˚C with 20 or 60 µmol/L of FAM-labeled peptide.
Cells were washed twice with PBS and fixed with Paraformaldehyde 4% (PFA) (Fisher Scien-
tific, Illkirch, France) for 20 minutes. After washing, coverslips were mounted with a Prolong
Gold antifade solution (Life Technologies). Finally, neurospheres were observed with a confo-
cal microscope (Leica TCS SP8; Leica Biosystems, Nanterre, France).
The peptide was also visualized in hNSCs together with different markers using immuno-
fluorescence. For this purpose, cells were seeded on coverslips coated with BD Cell-Tak as
described above, and then incubated 1 hour with FAM-labeled peptide and washed twice.
Then, they were fixed with PFA 4%, permeabilized 10 minutes with MTSB (PIPES 50 mmol/L;
MgSO4 5 mmol/L and EGTA 5 mmol/L) in PBS and saturated with BSA 4% in PBS. Two
washes were performed between each step. Cells were incubated overnight at 4˚C with the pri-
mary antibody (rabbit anti α-tubulin 1/500 (SAB3501072-Sigma); rabbit anti nestin 1/100
(N5413-sigma); or rabbit anti CD133 1/100 (18470-1-AP-Proteintech (Manchester–United
Kingdom)). After washing twice, the cells were incubated with AlexaFluor 568-coupled anti-
rabbit antibodies 1/200 (Invitrogen) for 90 minutes in the dark and washed twice. Finally, cells
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were counterstained with 3 µmol/L 4’6-diaminido-2-phenylindole (DAPI; Sigma) for seven
minutes and the coverslips were mounted with Prolong.
Cell viability and microtubule network disruption
The cell viability was evaluated with the AnnexinV-FITC Kit (Miltenyi, Paris, France) after 72
hours incubation of the cells with NFL-TBS.40-63 peptide or Paclitaxel. In short, cells were
seeded in 6-well plates and incubated with increasing concentrations of biotinylated peptide or
Paclitaxel (0.1 µmol/L) for 72 hours at 37˚C. The cells were collected and centrifuged at 1200
rpm for 10 minutes. Following washing and centrifugation (1200 rpm– 10 minutes), the cells
were stained with FITC-Annexin-V for 10 minutes at room temperature in the dark. Then, the
cells were washed, dissociated, counterstained with Propidium Iodide (PI) (1 µg/ml—Sigma)
and analyzed by FACS. A minimum of 10,000 events per sample were analyzed, followed by
data analysis with the Flowing Software (version 2.5.1).
The possible effect of the peptide on the microtubule network was analyzed using immuno-
fluorescence. The cells were first incubated for 24 hours with the FAM-NFL peptide, and then
stained with the anti-α-tubulin (1/500 T6199-Sigma). Primary antibody was exposed using the
AlexaFluor 568-coupled anti-mouse antibody 1/200 (Invitrogen), which was incubated for 90
minutes in the dark. After washing and counterstaining with DAPI, cells were visualized and
analyzed by confocal microscopy. The number of cells with disrupted microtubule network
was counted manually.
Cell proliferation and cell cycle analysis
To analyze the effect on the cell cycle, hNSCs were seeded in 6-well plates and treated for 72
hours with increasing concentrations of biotinylated-NFL-TBS.40-63 peptide, or with colchi-
cine at 1µg/ml. The cells were collected and centrifuged at 1200 rpm for 10 minutes, followed
by cells dissociation and permeabilization with Tween 0.1% in PBS. Then, the cells were fixed
with 70% ethanol, centrifuged and suspended in 1 mg/ml RNase for 30 minutes at 37˚C, and
analyzed by FACS after adding 10 µg/ml of PI. Proliferation of hNSCs was determined with
two techniques: the Trypan blue exclusion test and the CyQUANT assay kit (Fisher).
For the Trypan Blue exclusion test, neurospheres were seeded in 24-well plates and treated
for 72 hours with increasing concentrations of 1 µg/mL biotinylated peptide or colchicine. Neu-
rospheres were dissociated with Accumax enzyme, and the number of cells was counted follow-
ing Trypan blue (Sigma, dilution 1:2) staining. At least three wells per condition were analyzed.
For the CyQUANT assay tests, the cells were dissociated with Accumax enzyme, seeded
and treated with colchicine (1 µg/L) or increasing concentrations of NFL-TBS.40-63 peptide in
black 96-well plates. After 72 hours, supernatants were transferred on black 96-well plates
coated with BD Cell-Tak (3.5 µg/cm), and the cells were allowed to adhere for 1 hour. Then,
wells were washed twice with PBS and frozen at -80˚C for at least 24 hours. CyQUANT GR
dye buffer (200 µl) was added per well, and the fluorescence was measured with a fluorescence
microplate reader (Spectra max M2; Molecular Devices, Sunnyvale, USA) (excitation: 480 nm;
emission: 520 nm). All experiments were performed at least three times.
The number of cells in the replicative state was determined using BrdU fixation (colorimet-
ric technic) or EdU (FACS) labeling. FACS was performed using the Click-iT Plus EdU Flow
Cytometry Assay Kits (Fisher) following 72 hours incubation of increasing concentrations of
NFL peptide or with 1 µg/ml of colchicine. Briefly, after 72 hours treatment, cells were incu-
bated with 10 µmol/l of EdU for five hours. Cells were harvested and washed with 1% BSA in
PBS by centrifugation at 800g for 10 minutes. The Cells were fixed and permeabilized, with
washing between all stages. The cells were then incubated with the detect EdU, washed and
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analyzed by FACS. A minimum of 10,000 events per sample were analyzed, followed by data
analysis with the Flowing Software (version 2.5.1).
BrdU labeling was evaluated using the BrdU cell proliferation ELISA kit (Abcam, Cam-
bridge, UK). Briefly, cells were incubated with 1 µg/ml of colchicine or increasing concentra-
tions of NFL peptide for 72 hours on a BD Cell-Tak coated 96-well plates. Incubation of BrdU
was performed for five hours. Then, the cells were fixed and their DNA was denatured for 30
minutes with the fixative solution. The cells were washed and incubated with the anti-BrdU
antibody for 1 hour. BrdU was exposed using the HRP conjugated antibody and its TMB sub-
strate. Positive BrDU cells were analyzed by colorimetry (absorbance reading at 450 nm) with
a fluorescence microplate reader.
Neurosphere formation ability
Neurosphere formation was evaluated by counting neurospheres after 7 days in the presence
of the biotinylated-peptide. Briefly, the cells were dissociated with Accumax enzyme and
seeded in 24-well plates, with each well divided in five squares. The cells were treated with
increasing concentrations of peptide or colchicine (1 µg/ml) for 7 days, and the culture
medium changed after 4 days. Then, images of each well were captured five times with a
Power Stat G15 digital camera. The neurosphere number and size were measured with the
ImageJ software (NIH, USA). The number of neurospheres was reported by cm of surface. The
experiments were repeated at least three times.
Cell adhesion
To measure the number of cells that had adhered, the CyQUANT cell Proliferation Assay Kit
(Molecular Probes, Oregon, US) was used. Briefly, cells were dissociated and seeded in black
96-well plates (10,000 cells/well). hNSCs were treated with increasing concentrations of pep-
tide for 72 hours. Then, the wells were washed twice with PBS and frozen at -80˚C for at least
24 hours. CyQUANT GR dye buffer (200 µl) were added to each well, and the fluorescence
was measured with a fluorescence microplate reader (Spectra max M2) (excitation: 480 nm;
emission: 520 nm). All experiments were performed at least three times.
The cell adhesion was also investigated by immunofluorescence. Briefly, the cells were
treated with increasing concentrations of biotinylated peptide on coverslips without coating.
After 72 hours, all supernatants were transferred onto coverslips coated with BD Cell-Tak to
allow adhesion of cells. All coverslips were fixed with PFA 4%, washed and incubated for 10
minutes with permeabilized buffer. After washing with PBS, the cells were stained with Phal-
loïdine TRITC (P1951-Sigma) for 1 hour, washed and counterstained with DAPI.
Cell differentiation
To analyze the effect of the peptide on cell differentiation, hNSCs were seeded in 6-well plates
and treated with 20 or 60 µmol/L of biotinylated peptide for five days. The cells were collected
and centrifuged at 1200 rpm for 10 minutes, followed by dissociation for 10 minutes at 37˚C
with Accumax enzyme (Stemcell Technologies, Grenoble, France) and centrifugation at 2000
rpm for 10 minutes. The cells were incubated for 10 minutes in the dark with buffer (0.5%
BSA / 2 mmol/L EDTA in PBS) containing A2B5-PE (10 µg/ml) (Miltenyi Biotec, Auburn,
USA) at or CD90-PerCP-Cy5.5 (0.4 µg/ml) (Miltenyi Biotec) or at 4˚C in the dark for 10 min-
utes with buffer (0.5% BSA in PBS) containing O4-PE at 1/100 (Miltenyi Biotec). One milliliter
buffer was added before centrifugation at 2000 rpm for 10 minutes. The cells were stained with
calcein violet and analyzed by FACS after 20 minutes incubation. A minimum of 10,000 events
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by sample were analysed, followed by data analysis with the Flowing Software (version 2.5.1).
The graphics are performed with FCS express 6 Flow Cytometry software.
To study if the peptide loses efficiency in a conditioned medium that induces cell differentia-
tion, the cells were incubated in conditioned medium with or without peptide for 10 days.
Briefly, 6-well plates were coated with poly-D-lysine (100µg/ml Sigma) for 1 hour at 37˚C before
seeding hNSCs in the conditioned medium alone (control), or containing 20 µmol/l NFL pep-
tide or 60 µmol/l NFL peptide. The medium was changed every 4–5 days until experimentation.
The same protocol was used to evaluate differentiation by FACS with CD90, A2B5 and O4.
Cell differentiation was also investigated by RT-PCR (Reverse Transcription polymerase
chain reaction) with different probes from the four nervous system lineages (stem cell, neuron,
astrocyte and oligodendrocyte), after five days in the presence of increasing concentrations of
the peptide. All probes came from the “Plateforme d’Analyses Cellulaire et Mole´culaire”(PA-
CEM), University of Angers (France), as detailed in Table 1. Briefly, cells were seeded in 6-well
Table 1. Primer sequences used for reverse transcription-polymerase chain reaction.
Gene Full name NM accession Sequence
CD133 Prominin 1 NM 006017.2 For 5’CTCAGACTGGTAAATCCCCC
Rev 5’GACGCTTTGGTATAGAGTGC
CD44 CD44 molecule NM 001202557.1 For 5’GATCCTCCAGCTCCTTTCG
Rev 5’GGAATACACCTGCAAAGCG
CNP 2’,3’-cyclic nucleotide 3’phosphodiesterase NM 033133.4 For 5’CCAAGTTTTGTGACTACGGG
Rev 5’AGCTTGTCCACATCACTCG
DCX Doublecortin NM 001195553.1 For 5’GTACGTTTCTACCGCAATGG
NM 000555.3 Rev 5’ATCCATGCTTCCGATCTTCC
NM 178153.2
NM 178152.2
NM 178151.2
GALC Galactosylceramidase NM 000153.3 For 5’AGCATCACTTCACGCTACG
Rev 5’CTTCCTGCAATGAACACACC
GAPDH Glyceraldehyde-3-phosphate dehydrogenase NM 001256799.1 For 5’-CAAAAGGGTCATCATCTCTGC
NM 002046.4 Rev 5’ AGTTGTCATGGATGACCTTGG
GFAP Glial fibrillary acidic protein NM 002055.4 For 5’CTACAGGAAGCTGCTAGAGG
Rev 5’TTAATGACCTCTCCATCCCG
GLAST Solute carrier family 1 NM 001166696.2 For 5’TGCAAAGAAGAGACCCTCC
(glial high affinity glutamate transporter) Rev 5’CTGTGAGCAGCACAAAAGC
NCAM Neural cell adhesion molecule 1 NM 001242608.1 For 5’TACAAAGCTGAGTGGAGAGC
NM 001242607.1 Rev 5’CGTCTTGAACTCGGAGGC
NM 001076682.3
NM 181351.4
NM 000615.6
NESTIN Nestin NM 006617.1 For 5’AGAAACAGGGCCTACAGAG
Rev 5’AAAGCTGAGGGAAGTCTTG
SOX2 SRY-box2 NM 003106.3 For 5’GCAGTACAACTCCATGACCA
Rev 5’GATCATGTCCCGGAGGTC
TUBBIII Tubulin, beta 3 class III NM 006086.3 For 5’CCAGTATGAGGGAGATCG
Rev 5’CACGTACTTGTGAGAAGAGG
Accession numbers correspond to the transcripts for the gene. When several transcripts for the same gene exist, the probes were designed to amplify all transcripts.
https://doi.org/10.1371/journal.pone.0201578.t001
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plates and treated for five days with 20 or 60 µmol/L of NFL biotinylated peptide. The cells
were washed with PBS and frozen as dry pellet before RNA extraction and purification. The
total RNA extraction was performed with the RNeasy Micro kit (Qiagen, Courtaboeuf, France)
and the total extract was recovered in 14 µl RNase-free H2O. The reverse transcription in
cDNA was done with the Reverse Transcriptase SuperScript II Kit (Invitrogen). The purifica-
tion of cDNA was done with the QIAquick PCR Purification Kit (Qiagen). In total, 40 µl puri-
fied cDNA were recovered. Quantitative RT-PCR was achieved with the Maxima SYBR Green
qPCR master mix (Fermentas/ThermoFisher Scientific). The amount of cDNA was normal-
ized with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the relative gene
expression was compared to the control condition using the 2-ΔΔCt method [16].
Statistical analysis
All experiments were repeated at least three times. Results were presented as mean ± standard
error of the mean (SEM). Multiple group comparisons were performed with Tukey’s Honest sig-
nificant Difference test or Sidak using Prism version 7.00 (GraphPad PRISM software). Asterisks
indicate significantly different results:  P0.05;  P0.01;  P0.001; P0.0001.
Results
We first investigated the uptake of the neurofilament-derived peptide NFL-TBS.40-63 in
hNSCs and its internalization mechanism. Then, we analyzed the effects of this peptide on cell
viability and hNSC properties.
Uptake of NFL-TBS.40-63 peptide by hNSCs occurs by a passive direct
translocation
Cells were incubated for 1 hour with increasing concentrations of FAM-labeled NFL-TBS.40-
63 peptide, and the percentage of labeled-cells was analyzed by flow cytometry (Fig 1A). At 5
µmol/L, the peptide was internalized by 38.38 ± 2.90% of cells, whereas at 20 µmol/L it was
internalized by 76.34 ± 1.62% of cells. A maximum was reached for 40 µmol/L of peptide.
These results were confirmed by microscopy after incubating the cells for 1 hour with the
FAM-peptide and visualization by confocal microscopy (Fig 1B).
The influence of low temperature, ATP depletion and endocytosis inhibitors were analyzed
to assess whether internalization depends on endocytosis pathways. Unlike endocytosis path-
ways, direct translocation is an energy and temperature independent pathway. Thus, the direct
translocation mechanism of penetration can be shown by reducing the temperature to 4˚C or
depleting ATP (source of energy) [17].
First, we studied the temperature and energy dependent pathways by pre-treatment of NSCs
for 30 minutes at 4˚C or with a buffer containing 10 mmol/L sodium azide and 6 mmol/L
2-deoxy-D-glucose (ATP-depleted buffer), before adding the NFL peptide (20 µmol/L) in the
same conditions for 1 hour. Neither the low temperature nor the ATP depletion condition mod-
ified peptide internalization (81.29 ± 6.89% and 88.76 ± 1.53%, respectively, compared with
77.80 ± 1.70% in control; Fig 1C). These results indicate that peptide uptake by hNSCs occurs
via a direct translocation passive mechanism. To really exclude the active pathways, cells were
pre-incubated with a complete panel of inhibitors against the three principal endocytosis path-
ways: chlorpromazine, nystatin and DMA [18]. Chlorpromazine inhibits clathrin-dependent
endocytosis by reversible translocation of clathrin and its adapter proteins from the membrane
to intracellular vesicles [19]. Nystatin inhibits caveolin-dependent endocytosis by depletion of
cholesterol from caveolae [20], while DMA is known to inhibit micropinocytosis by inhibition
of the Na+/H+ exchange. The presence of these inhibitors did not prevent peptide
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internalization (Fig 1D), which still stained approximately 80% of the cells. These data con-
firmed that uptake of NFL peptide in hNSCs occurs via a passive pathway. The peptide can be
visualized by immunofluorescence thanks to fluorescein, and cells were also stained with α-
tubulin (Fig 1F) or with specialized-NSCs markers: Nestin and CD133 (Fig 1E). All the raw data
supporting these results are available (S1 File).
The NFL-TBS.40-63 peptide has no effect on cell viability and microtubule
network
Paclitaxel (Taxol) (for the cell viability) or colchicine (for all other experiments) were used as
positive controls. To study potential effects of the peptide on hNSCs, we evaluated the viability
of hNSCs after 72 hours incubation with the NFL peptide, at different concentrations, using
the flow cytometry technique with the Annexin-V-FITC/PI assay kit. Fig 2A shows the per-
centage of viable cells (control: 80.31 ± 3.585%). Taxol at 0.1 µmol/L was used as a positive
control to reduce viability (50.92 ± 3.122%). The NFL peptide has no major effect on the viabil-
ity of cells up to 40 µmol/L (74.10 ± 2.888 at 20 µmol/L and 68.99 ± 7.922 at 40 µmol/L). At 60
µmol/L, viability was reduced to 50.94 ± 4.207%. These results show that the NFL-TBS.40-63
peptide has no major effect on the viability of hNSCs below 40 µmol/L (Figs 2A and S1A). All
the raw data supporting these results are available (S1 File).
Then, we investigated the effect on the microtubule network by incubating hNSCs with
increasing amounts of peptide (20 or 60 µmol/L) for 24 hours. Fig 2B and 2C show the micro-
tubule network of cells stained with an anti-α-tubulin antibody and their quantification. The
microscopy visualization showed that no major difference was observed between control cells
and those treated with the NFL peptide, unlike with colchicine where there are fewer exten-
sions and an altered microtubule network (Fig 2B). Quantification confirmed that only the col-
chicine treatment was able to alter the microtubule network (13.67 ± 2.455% of cells with
disrupted MT network compared with 38.29 ± 7.781%, control condition and colchicine
respectively. 13.57 ± 1.853 and 15.40 ± 2.789% corresponding to NFL 20 and 60 µmol/l, respec-
tively; Fig 2C). These results demonstrate that the peptide had no major effect on the microtu-
bule network.
Effects of the NFL-TBS.40-63 peptide on the proliferative properties of
hNSCs
We analyzed the effect of increasing concentrations of the peptide for 72 hours on the cell
cycle (Fig 3A). We used colchicine as a positive control to block cells in the G2/M phase [21]
(13.12 ± 1.97% against 5.9 ± 0.76%, in respectively colchicine or control conditions). The cell
cycle of hNSCs was not significantly modified by the NFL-TBS.40-63 peptide (G0/G1 phase:
80.53±4.62% vs 68.5±3.84%, S phase: 13.57±4.14% vs 20.07±4.04%, G2/M phase: 5.9±0.76% vs
11.03±2.7%, condition control and NFL-TBS.40-63 at 20 µmol/L, respectively; Fig 3A). How-
ever, results point towards a decrease of G0/G1 phase and an increase of the other two cell
cycle phases. To further explore this effect, we also analyzed the incorporation of thymidine
analogues (BrdU and EdU– 5 hours incubation) after 72 hours treatment with the NFL
Fig 1. Uptake of the FAM-labeled NFL-TBS.40-63 peptide in hNSCs. (A) Percentage of FAM-labeled NFL-TBS.40-63 internalized by hNSCs with
increasing concentrations of peptide after 1 hour incubation at 37˚C. (B) Visualization of the FAM-labeled peptide after 1 hour incubation with 20
or 60 µmol/L of peptide. Scale bar: 50 µm. Green: FAM-labeled peptide (C) Internalization of 20 µmol/L of peptide after pre-treatment at 4˚C or
ATP depletion or (D) in the presence of inhibitors of the endocytosis pathways. Data are presented as means ± SEM. P<0.05. (E-F)
Immunofluorescence after incubation of cells for 1 hour with 20 or 60 µmol/L FAM-labeled peptide. Cells were stained with specific neural stem
cells markers: Nestin and CD133 (E) or with α-tubulin (F). Images were taken with the confocal microscope. Red: Nestin, CD133 or α-tubulin;
Green: FAM-labeled peptide; Blue: DAPI. Scale bar: 50 µm.
https://doi.org/10.1371/journal.pone.0201578.g001
The NFL-TBS.40-63 peptide is internalized by hNSCs and affects their properties
PLOS ONE | https://doi.org/10.1371/journal.pone.0201578 August 9, 2018 9 / 22
peptide. We observed that the integration of both analogues seemed to be increased with
increased concentrations of the peptide, while the incorporation was reduced in the presence
of colchicine (Figs 3B, 3C and S1B). Indeed, EdU incorporation increased from 24.7 ± 7.605%
in control to 50.11 ± 13.04 or 62.38 ±11.11 with respectively 20 or 60 µmol/l of peptide, and
decreased at 0.65 ± 0.2723 with colchicine.
Next, we determined if proliferation could be affected by the presence of the peptide. To
that end, we quantified the cell number after 72 hours incubation using two techniques. The
first approach used cell quantification with Trypan blue exclusion (Fig 3D). The number of
cells in each experiment was compared to the number of cells in the control condition. The
Fig 2. The NFL-TBS.40-63 peptide has no toxic effect on cell viability and the microtubule network. (A) Percentage of viable cells was evaluated after
incubation for 72 hours with increasing concentrations of NFL-TBS.40-63 peptide or with Taxol (0.1 µmol/L). Cell viability was measured by FACS (Annexin-
V-FITC / PI assay kit). (B) Effect of 20 or 60 µmol/L of FAM peptide (green) on the microtubule network (α-tubulin: red; NFL FAM peptide: green) after 24 hours.
Images were taken with the confocal microscope. Scale bar: 20 µm. (C) Percentage of cells with a disrupted microtubule network in control condition, or with
different treatments (colchicine, NFL 20 or 60 µmol/l). Data presented as means ± SEM. P<0.01.
https://doi.org/10.1371/journal.pone.0201578.g002
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Fig 3. The NFL-TBS.40-63 peptide affects the proliferation of hNSCs. (A) Percentage of hNSCs at G0/G1, S or G2/M of the cell cycle after
treatment with colchicine (1µg/ml) or increasing concentrations of biotinylated-NFL-TBS.40-63 peptide. Data are presented as means ± SEM.
The NFL-TBS.40-63 peptide is internalized by hNSCs and affects their properties
PLOS ONE | https://doi.org/10.1371/journal.pone.0201578 August 9, 2018 11 / 22
presence of colchicine reduced cell number by about 75% when compared to control
(35.09 ± 8.68%). When cells were incubated with increasing concentrations of peptide, cell
number was significantly reduced in a dose-dependent manner (Fig 3D; 20 µmol/L:
47.68 ± 14.59% and 60 µmol/L: 24.48 ± 9.79%). Similar results were obtained using the second
method, where nuclei were stained with a fluorescent probe (CyQUANT GR) (Fig 3E). The
number of cells after 72 hours was gradually decreased when hNSCs were incubated with
increasing concentrations of peptide, thus confirming the anti-proliferative effect of the pep-
tide on hNSCs (117.2 ± 20.38 AU in control conditions compared with 88.53 ± 10.39 AU at 20
µmol/L; 61.28 ± 8.607 AU at 40 µmol/L and 49.86 ± 8.023 AU at 60 µmol/L).
Effect on neurosphere formation
Then, we evaluated the ability of hNSCs to create new neurospheres. Each dissociated cell can
create a clone of itself in proliferative medium to form a neurosphere. After 7 days of culture
in the presence of increasing concentrations of peptide or colchicine (1 µg/ml), we quantified
the number and the size of spheres. Fig 4A represents the average number of spheres per
square centimeter after 7 days of culture. The number of neurospheres was significantly
decreased with 20 µmol/L of NFL-TBS.40-63 peptide, as well as in the presence of 60 µmol/L
of peptide. Moreover, the size of the neurospheres was also reduced in the presence of the pep-
tide (Fig 4B). Both number and size of neurospheres after 7 days of culture with 1 µg/ml of col-
chicine were reduced by 60%. Fig 4C represents typical neurospheres after 7 days in control
conditions, or in the presence of colchicine, or with 20 and 60 µmol/L of peptide. In control
conditions, the neurospheres were round, while only individual cells were found in the pres-
ence of colchicine. The presence of 20 µmol/L or 60 µmol/L of peptide induced an increased
number of adhesive cells, which lost the round shape typical of neurospheres (Fig 4C).
We also quantified the number of cells that were still adhering with the CyQUANT assay
kit. The number of adherent cells proportionally increased with the increased concentration of
the peptide. We noticed a significant increase of cell adhesion with 40 µmol/L of peptide (from
259.8 ± 25.11 in control conditions to 396.1 ± 31.49 with 40 µmol/L of NFL peptide; Fig 4D).
We further confirmed these results using fluorescence staining on coverslips without any coat-
ing. Fig 4E (left panels) shows that an increased number of cells was systematically observed in
the presence of 60 µmol/L of peptide, and when compared to the absence of peptide. To be
sure that the same number of cells was seeded on coverslips, all supernatants were transferred
on BD Cell-Tak coated coverslips (Fig 4E, right panels), and then incubated for 1 hour before
being stained. Thus, neurospheres that were floating in the control condition (without peptide)
were all observed because they adhere on BD Cell-Tak coverslips. In contrast, no neurospheres
were floating in the presence of 60 µmol/L of peptide, because no neurospheres were observed
when the supernatant was transferred on BD Cell-Tak coated coverslips. No major difference
was observed between the control (no peptide) and 20 µmol/L of peptide, as shown after quan-
tification with the CyQUANT assay kit (259.8 ± 25.11 UA compared with 296,8 ± 28.34 UA in
controls or with 20 µmol/L, respectively). Taken together, these data indicate that the peptide
induces increased cell adhesion. Since the increased adherence of cells can be correlated with
(B-C) Thymidine analogue incorporation: The number of BrdU (B) or EdU positive cells (C) was counted after 72 hours incubation with 1 µg/
ml of colchicine or with increasing concentrations of peptide, and compared to the control condition. Thymidine analogues were incubated for
5 hours before the end of the test. Data presented as means ± SEM. (D-E) Cell proliferation: Number of cells after 72 hours incubation with the
NFL peptide was quantified using Trypan blue exclusion (D) or using the CyQUANT assay (E). P<0.05, P<0.01, P<0.001,
P<0,0001.
https://doi.org/10.1371/journal.pone.0201578.g003
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Fig 4. The NFL-TBS.40-63 peptide affects the capability to form neurospheres and increase adhesion of hNSCs. (A-C) Sphere formation from
hNSCs: quantification of the number of neurospheres per square centimeter (A) and their size (B) after 7 days incubation with increasing
concentrations of the peptide, or with 1 µg/ml of colchicine. Scale bar: 150 µm. (C) Morphology of neurospheres observed after 7 days incubation in
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an increased number of differentiating cells, we next evaluated the effect of the peptide on the
differentiation process.
Effect on hNSC differentiation
We first investigated the neural/neuronal or glial differentiation of hNSCs by quantifying the
glial or neuronal progenitor markers (A2B5 and CD90, respectively) and the pre-oligodendro-
cyte marker (O4), by FACS technique after 5 days in culture in a proliferative medium con-
taining 20 or 60 µmol/L of peptide. We show that all the markers were increased by the
presence of peptide (Fig 5A) in a proliferative medium (CD90: 0.0825 ± 3.663 in controls vs
3.663 ± 0.556 at 20 µmol/L and 18.65 ± 3.983 at 60 µmol/L; A2B5: 1.193 ± 0.4333 in controls vs
4.037 ± 1.687 at 20 µmol/L and 30.21 ± 4.939 at 60 µmol/L; O4: 0.847 ± 0.5733 in controls vs
10.47 ± 2.504 at 20 µmol/L and 24.07 ± 3.344 at 60 µmol/L). These results indicate that cells
move towards a more differentiated state after 5 days in the presence of the peptide. No specific
pathway seems to be induced by the peptide since the three markers were similarly increased.
We also determined whether the fate of hNSCs in a conditioned medium could be affected
by the presence of the peptide. We observed that in conditioned medium (control condition),
cells express more markers of differentiation than in proliferative medium (CD90: 2.22 ± 1.007;
A2B5: 5.593 ± 2.334; O4: 3.953 ± 1.961 in conditioned medium). Moreover, the presence of pep-
tide does not seem to induce a specific differentiating pathway when cells are incubated in the
conditioned versus the proliferative medium. However, the differentiation pathway was boosted
by the peptide in the conditioned medium (for both peptide concentrations). The conditioned
medium stimulates the differentiation of cells in the three pathways, and the peptide over-stim-
ulates this differentiation, but without increasing a selective pathway.
To better characterize the differentiation of hNSCs after 5 days in the presence of the NFL-
peptide, a RT-qPCR screening was performed using different markers from the four differenti-
ation pathways (stem cell, neuron, astrocyte or oligodendrocyte; Fig 5B). At 20 µmol/L of pep-
tide, NESTIN and SOX2 gene expression was increased, while it was not increased at 60 µmol/
L. The peptide at both concentrations decreased the expression of the CD133marker. The neu-
ron-specific markers BIII-tubulin and DCXwere increased at 60 µmol/L of peptide, indicating
a commitment towards the neuronal differentiation pathway. While the astrocyte markers
(GFAP and CD44) were overexpressed (more than 10 times compared to the control condi-
tion) with increasing concentrations of peptide, the GLAST marker was reduced. The oligo-
dendrocyte marker CNP was not modified by the presence of the peptide unlike the GALC
marker, which was decreased with 60 µmol/L of peptide. Immunofluorescence using antibod-
ies revealed similar effects, but the differences were not as obvious as the RT-qPCR technique
because of the very slow growth of these cells (not shown).
Discussion
The possibility of manipulating NSCs directly in the brain for neurodegenerative therapies
would be a major breakthrough in the context of neurological disorders. As previously shown,
the NFL-TBS.40-63 peptide is a promising tool to target newborn or adult rat NSCs by
normal conditions, or with colchicine, or with the NFL peptide at 20 or 60 µmol/L. (D-E) Quantification of adherent cells after 72 hours with
increasing concentrations of NFL peptide using the CyQUANT assay (D) or by immunostaining of cells after 72 hours with increasing concentrations
of biotinylated peptide (E). Adherent cells were observed on coverslips without coating (top pictures), while non-adherent (floating) cells were
recovered following centrifugation and 1 hour incubation on BD Cell-Tak coated coverslips (Bottom pictures). Cells were visualized by Phalloïdin
staining (red) and DAPI staining the nucleus (blue). Scale bar: 100 µm. Data presented as means ± SEM. P<0.05, P<0.01, P<0.001,
P<0,0001.
https://doi.org/10.1371/journal.pone.0201578.g004
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Fig 5. The NFL-TBS.40-63 peptide increases differentiation of hNSCs. (A-B) Differentiation of cells induced after 5 days by increasing
concentrations of NFL peptide in a proliferative or conditioned medium. (A) Percentage of cells which express the neuronal marker CD90 (top
The NFL-TBS.40-63 peptide is internalized by hNSCs and affects their properties
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modifing their behavior [12]. It is however essential to first evaluate the potential of this pep-
tide to modify human NSCs before considering this strategy as a therapeutic approach. Here,
we show that the peptide NFL-TBS.40-63 is able to enter hNSCs by direct translocation, with-
out a major effect on cell viability at low concentrations (below 40 µmol/L). However, above
20 µmol/L, the peptide decreases hNSC proliferation and their capability to form neuro-
spheres, which is consistent with an increase in cell adhesion and differentiation in the neuro-
nal and astrocytic pathways. Taken together, these results show for the first time that a peptide
is well internalized in NSCs from human fetuses and it modifies hNSC properties including
proliferation and differentiation.
The peptide NFL-TBS.40-63 is able to enter in NSCs from human fetus in a dose-dependent
manner as previously shown for NSCs from newborn and adult rats [12] or glioblastoma cells
[22, 23]. It was also internalized by oligodendrocytes [24] and certain human tumor cell lines
(HeLa, MCF7, LNCaP) [9, 22], while its internalization was very low in healthy astrocytes or
neurons [11, 22]. However, the internalization pathway was not the same for all of these cells.
While NFL-TBS.40-63 uptake occurs through clathrin endocytosis in oligodendrocytes [24],
or through the three endocytosis pathways in glioblastoma cells [23], it was internalized by
direct translocation (an energy and temperature independent pathway), both in human and
rat derived NSCs [12]. These different uptake mechanisms could be due to the composition of
the membrane. Indeed, interactions between the charges of the peptide and membrane can be
affected by membrane components, as already shown for other cell-penetrating peptides [25].
Furthermore, as previously described, the high proliferative activity of glioblastoma cells can
account for the massive NFL peptide internalization [23]. Stem cells [26] and tumor cells are
also proliferative cells, when compared to neurons [27] or astrocytes [28] that progressively
diminish their proliferation rates during differentiation. This observation supports the idea
that this peptide at low concentration would be a promising tool to target NSCs of the central
nervous system without affecting neurons and astrocytes. Interestingly, the viability of hNSCs
was not particularly affected by the peptide, except at high concentration (60 µmol/L), where
half of the cells survived. We used Paclitaxel instead of colchicine to study cell viability because
colchicine did not significantly affect cell viability, as already reported for other cells like HL-1
cells [29]. The effect of Paclitaxel was not very important, and this could be due to the strong
resistance of stem cells to these drugs, as shown previously for mesenchymal stem cells [30].
The NFL-TBS.40-63 peptide has multiple effects on glioblastoma cells where it enters mas-
sively. In particular, it destroys their microtubule network, stops the cell cycle, and reduces
their proliferation and migration [22]. Here, we show that the microtubule network of hNSCs
is not affected by the peptide even at high concentrations, while the microtubule network in
glioblastoma cells is affected even at low concentrations (10 µmol/L) [22]. This differential
effect on the microtubule network could be explained by a tubulin specifically expressed in
glioblastoma cells, which is not present in NSCs. Indeed, docking experiments between the
NFL peptide and tubulin indicate that the peptide binds on a site located near the β-tubulin C-
terminal end [31]. Moreover, similar docking experiments showed that the conformation of
the β-tubulin C-terminal domain is important for the binding of the peptide. Indeed, the C-
graph), the glial marker A2B5 (medium graph) or the oligodendroglial marker O4 (bottom graph) after 5 days in the presence of the NFL peptide at
20 or 60 µmol/L in the proliferative medium (white bars) or the conditioned medium (dark bar). Markers were analyzed by FACS technique and
some examples are given in the left part of each graph. (B) The relative expression level of CD133,Nestin, Sox2, βIII tubulin, DCX,NCAM, GFAP,
CD44,GLAST, GALC, CNP genes was quantified by reverse transcription polymerase chain reaction after 5 days with 0 (control condition), 20 or 60
µmol/L of peptide. The relative gene expression was compared with control conditions after normalization with the GAPDH gene (value of the
control condition = 1) with the 2-ΔΔCt method. All data were presented as means ± SEM. P<0.05, P<0.01, P<0.001, P<0,0001. Stars
above bars represent significant data compared to control.
https://doi.org/10.1371/journal.pone.0201578.g005
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terminal region of βI tubulin, but not of βIII tubulin, forms internal contacts preventing the
binding of the peptide on tubulin [32]. Finally it was shown that β-tubulins are differentially
expressed depending on the tissue [33]. The βII-tubulin isotype is found in NSCs [34], while
βIII-tubulin is overexpressed in human glioblastoma cells and breast cancer cells [35], where
the NFL-TBS.40-63 peptide affects the microtubule network [9]. Interestingly, the
NFL-TBS.40-63 peptide does not affect microtubules in mature neurons, which slightly
express βIII-tubulin [22]. Taken together, these data suggest that the specific effect of the pep-
tide on microtubules may be due to a specific post-transcriptional modification of the βIII-
tubulin, which is present in several cancer cells, but absent in NSCs.
When investigating the effect of the peptide on properties of hNSCs, our data suggest that
they lose their stem cell characteristics. Using FACS analysis (Propidium Iodide incorpo-
ration) we observed that the cell cycle (G0/G1, G2/M, S phases) was not dramatically modified
by the presence of the peptide, but cells were mostly in G2/M and S phases in the presence of
peptide (when compared to control conditions). We also measured the incorporation of two
thymidine analogues (BrdU and EdU) to investigate the replicative state of cells. Such ana-
logues are incorporated only in the replicative stage of the DNA (during the synthesis stage–
phase S). Here, we observed that the peptide increased the incorporation of these analogues
after 72 hours. We expected also to have a significant increase in the number of cells in S phase
with the FACS technique because of the observed BrdU and EdU increase. This was not the
case, and it could be explained by the fact that FACS is a technique, which takes cells in a punc-
tual point compared to BrdU/EdU, where cells are incubated during 5 hours. Cells could have
already completed S phase during this period and currently be in G2/M phase or return to G0
phase (differentiated cells for example). Thus, at the time of FACS measurement, BrdU posi-
tive cells could be detected as G2/M cells or G0/G1 cells. Moreover, the FACS method cannot
distinguish between early and late S phase (late G1 phase and early G2 phase, respectively).
Paradoxically, the presence of the peptide, even at low concentrations (20 µmol/L) in the
culture medium of hNSCs during 3 days, induces a significant decrease of the number of
hNSC (Trypan blue and Cyquant tests). The effect with 60 µmol/L of peptide was comparable
to the effect of colchicine, which indicates a potential toxic effect of the peptide at this high
concentration.
When incubated in the right medium (proliferative medium), NSCs form neurospheres in
suspension after few days, but fewer neurospheres were formed in the presence of the peptide.
These results are consistent with a decrease in the number of cells and an increase in adhesion
after 72 hours. Moreover, the size of neurospheres was also reduced as a consequence of the
decrease of cell proliferation (number of cells) as soon as 72 hours as previously described
[36]. This decrease in size could be explained by the uptake of the NFL peptide in the fast
dividing cells as previously shown [23]. Indeed, there are heterogeneous cells in neurospheres,
with a small proportion being either slow dividing or fast dividing cells and the proportion of
each cell population modifies the size of the neurosphere [37]. We do not know the exact
mechanism of inhibition of hNSC proliferation in the long run, but it can be a consequence of
the effect of NFL-TBS.40-63 peptide on mitochondria network as previously observed in glio-
blastoma [38]. Indeed, the mitochondria network is closely linked to the proliferation mecha-
nism thanks to the aspartate synthesis [39], and thus the peptide at low concentration could
affect the mitochondria in hNSCs inducing a reduction in proliferation. Moreover, as previ-
ously mentioned, the peptide is derived from the tubulin binding site of neuron-specific cyto-
skeleton protein (neurofilament), which suggests that the peptide has more affinity with
neuron-specific tubulin (like βIII tubulin) than other tubulins as previously shown [32]. Since
all sequences of β-tubulin are very similar [40], it is possible than the NFL-TBS.40-63 peptide
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binds other tubulins with less affinity than with the βIII tubulin, resulting in modification of
proliferation without affecting the microtubule network.
Several peptides, endogenous or not, were shown to promote proliferation and migration
of these cells [41, 42] but none of them had an inhibitory effect on proliferation. To assess
whether adhered cells were more differentiated, we studied the expression of several differenti-
ation markers. We first investigated the protein expression of neuronal (CD90) and glial
(A2B5 and O4) progenitor markers. We showed an increase expression for neuronal and glial
markers in treated cells after 5 days confirming a differentiation towards the neuronal and
glial pathways. This technique does not allow discriminating between astrocytic and oligoden-
drocytic pathways. We further investigated the gene expression of the four pathways (stem
cell, neuron, astrocyte and oligodendrocyte). Interestingly, the RT-PCR analysis showed
decreased expression of CD133, a stem cell specific marker. NESTIN and SOX2 expression
were increased after treatment, but both markers are also expressed by neural progenitors
[43], suggesting a neuronal commitment of the cells. The mRNA of early neuronal markers
Tubulin βIII and DCXwere both increased at 60 µmol/L of NFL peptide, validating the more
advanced neuronal state. NCAM which was not modified with the peptide, is expressed partic-
ularly by mature neurons, suggesting that cells do not differentiate towards a mature neuronal
phenotype [44]. The astrocyte marker GFAP was increased with both concentrations of NFL
peptide, while CD44was only increased at 60 µmol/L, suggesting an engagement towards
astrocytic differentiation of the cells. To be sure that we only visualized GFAP expressed by
astrocytes, we did not study the delta isoform of GFAP which is expressed by neural stem cells
[45]. GLAST is expressed by fetal stem cells [46], and thus the decrease of GLAST expression
induced by the peptide could support the loss of stem cell properties. A study has already
shown that some human neural stem cells can express the GALC marker [47]. The oligoden-
drocyte pathway did not seem to be modified by the presence of the peptide in hNSCs. These
data explain the expression of GALC in our cells and the decreased expression with 60 µmol/L
of peptide, which correlated with the loss of stem cell property.
These results could be consistent with a reduction of the number of cells and an increase of
adhesion after 72 hours: peptide induces production of differentiated cells, which are post-
mitotic cells. We also evaluated whether cells growing in a conditioned medium with peptide
could induce differentiation in a specific manner. Even if we had more differentiated cells in
the conditioned medium (versus the proliferating medium), the addition of the peptide does
not induce cell differentiation in a particular pathway after 10 days in culture. The conditioned
medium stimulates the differentiation of cells in the three pathways, and the peptide over-
stimulates this differentiation, but without increasing a selective pathway.
In summary, the number of cells was reduced after 3 days of culture as well as the capability
to form neurospheres while cell adhesion and differentiation were increased in the presence of
peptide. To our knowledge, this is the first report to show that a peptide can penetrate NSCs so
efficiently and modify their properties. The peptide has no major effect on these cells at low
concentration (less than 20 µm/L), while at higher concentration it inhibits proliferation and
the capability to form neurospheres, as well as, increases cell adhesion and differentiation in a
proliferative medium. Indeed, all experiments were performed using proliferative medium,
and because this peptide is able to stimulate hNSC differentiation in this medium, it would be
interesting to counteract the inconvenient transfer of cells in defined medium. Indeed, this
peptide could be an interesting tool to target and differentiation endogenous NSCs after intra-
ventricular injection in human patients with neuronal disease, since it is not able to penetrate
inside healthy astrocytes or neurons [22]. Further experimentation will be done to describe
and detail the mechanism of action for the NFL-TBS.40-63 peptide.
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Conclusions
Previous works showed that the NFL-TBS.40-63 peptide penetrates in NSCs from newborn
and adult rats, where it affects their properties, in particular increasing differentiation in neural
pathways [12]. Here, we show that this peptide also enters by direct translocation in human
NSCs in a dose-dependent manner. The peptide induces a decrease in hNSC proliferation,
consistent with an increase in cell adhesion and differentiation in the neuronal and astrocytic
pathways. This peptide could be used as a targeting tool following its absorption on nanoparti-
cles as previously shown in glioblastoma cells [48] or rat NSCs [49]. Therefore, this peptide
represents a promising new tool to target and manipulate NSCs in the case of neurodegenera-
tive diseases, as well as to bring nanoparticles selectively in such cells.
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